Entropy Neurodynamics Limited (ASX: ENP) - Share Price

- Current share price for ENP : $0.032

Entropy Neurodynamics Limited (ENP, formerly Tryptamine Therapeutics Limited) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It , is a clinical-stage biotechnology company focused on developing patented, original formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs.

ENP General Information ⁺

ASX Code	ENP
Website	http://www.tryptherapeutics.com
Industry/Sector	Pharmaceuticals
Market Cap ($M)	52
ENP Share Price	$0.032
Day High	$0.033
Day Low	$0.032
Last Close	$0.032
ENP Share Price Movement	- ( No change )

Prices as at 16:40, 22 Oct 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Entropy Neurodynamics Limited (ENP) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Entropy Neurodynamics Limited (ENP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Entropy Neurodynamics Limited (ENP) price-sensitive announcements

ENP - TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study

Entropy Neurodynamics Limited (ASX: ENP) announced that the first patient in Cohort 2 of i

Entropy Neurodynamics Limited (ENP)
7 Oct 2026 | 9:11 AM

ENP - All Patients Improve, 50% Achieve 12-Week BED Remission

Entropy Neurodynamics announced 12-week follow-up results from Cohort 1 of its Phase 2 tri

Entropy Neurodynamics Limited (ENP)
14 Sep 2026 | 8:40 AM

ENP - Appendix 4E and 2026 Annual Report

Entropy Neurodynamics Limited’s Appendix 4E and 2026 Annual Report for the Australian fina

Entropy Neurodynamics Limited (ENP)
28 Aug 2026 | 9:44 AM

ENP - Entropy Advances TRP-8803 to US Phase 2 in Depression

Entropy Neurodynamics Limited, an Australian clinical-stage biotechnology company, is set

Entropy Neurodynamics Limited (ENP)
26 Aug 2026 | 9:57 AM

Entropy Neurodynamics Limited (ENP) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$52	Entropy presents promising TRP-8803 clinical data at ECNP	19 Oct 2026 8:46AM	$0.035	$0.032	fallen by 8.57%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$52	Change of Director's Interest Notice - HJ	14 Oct 2026 12:13PM	$0.036	$0.032	fallen by 9.86%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$52	Cleansing Notice	14 Oct 2026 12:10PM	$0.036	$0.032	fallen by 9.86%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$52	Application for quotation of securities - ENP	14 Oct 2026 12:07PM	$0.036	$0.032	fallen by 11.11%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$52	TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study	7 Oct 2026 9:11AM	$0.038	$0.032	fallen by 15.79%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$52	2026 AGM Notice of Meeting, Letter of Access and Proxy	5 Oct 2026 8:50AM	$0.039	$0.032	fallen by 17.95%

ENP Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2026A	-$4.87	-$0.30	-18.40%	0.00%	0.0%
2025A	-$5.19	-$0.40	-56.30%	0.00%	0.0%
2024A	-$4.39	-$0.90	-76.00%	0.00%	0.0%

ENP Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A	2024 A	2025 A	2026 A
Clarity Pharmaceuticals Ltd (CU6)	$664M	0.4454	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Entropy Neurodynamics Limited (ENP)	$52M	-0.1842	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,497M	-0.7857	0.2462	0.9655	84.6584	67.9310	34.5614	0.00%	1.68%	1.98%

ENP Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	7.27	0.00
Market	0.30	13.50	1.04	0.71
Sector	0.78	40.70	2.39	2.09

ENP Directors

Name	Position	Start Date
Mr Jason Alan Carroll	Chief Executive Officer, Managing Director	1 May 2024
Mr Christopher Ntoumenopoulos	Executive Director	1 May 2024
Mr Herwig Janssen	Non-Executive Chairman, Non-Executive Director	12 May 2025
Dr Daniel Tillett	Non-Executive Director	8 Nov 2024
Mr Gage Jull	Non-Executive Director	1 May 2024

Entropy Neurodynamics Limited (ENP) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
14 Oct 2026	JANSSEN, Herwig	Issued	Direct Shares	623,441	$0.040	$25,000.000
7 Aug 2026	JANSSEN, Herwig	Issued	Direct Shares	766,871	$0.033	$25,000.000
13 May 2026	CARROLL, Jason	Buy	Direct Shares	538,236	$0.036	$19,376.000

See all changes in directors' interest & trades for Entropy Neurodynamics Limited (ENP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ENP Management

Name	Position
Hamish George	Joint Company Secretary
Meghna Piplani	Joint Company Secretary
Jim Gilligan	Other Corporate Officer

ENP Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Entropy Neurodynamics Limited (ENP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
222,454,729 (13.63%)	William Garner
99,376,907 (6.09%)	Citicorp Nominees Pty Limited

ENP Calendar of Events

Date	Event
27 August 2027	Report (Annual)
27 August 2027	Report (Prelim)
26 February 2027	Report (Interim)
12 November 2026	AGM

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us